The combination of PPARγ ligands and inhibitors againstreceptor tyrosine kinases of the EGFR-family or cytoplasmic tyrosine kinases(e.g., Abl) revealed some promising results in leukemia and carcinoma cells.Gefitinib, an inhibitor of the EGFR/Her1 kinase, exhibits antitumor activity inonly a fraction of 10–20% of patientswith nonsmall cell lung cancer (NSCLC) [144]. Here, PPARG is linked to leukemia.